EU Officially Approves Rapeseed Oil as a Low-Risk Active Substance Until 2040
On September 17, 2025, the European Commission published Regulation (EU) 2025/1879 in the Official Journal of the European Union, formally approving rapeseed oil as a low-risk active substance under the EU’s Plant Protection Products Regulation framework.
According to the legislation, the approval of rapeseed oil is valid until October 31, 2040, providing a 15-year authorization period, which is the maximum duration generally granted for low-risk substances. The regulation will enter into force on the twentieth day following its publication, ensuring timely implementation across EU Member States.
This approval underscores the EU’s commitment to sustainable and environmentally friendly pest management. Rapeseed oil, a biodegradable and non-toxic natural compound, is widely used as a botanical insecticide and fungicide, offering an effective and safe alternative to synthetic pesticides. The decision supports the European Green Deal and Farm to Fork Strategy, both of which aim to reduce pesticide dependency and promote bio-based agricultural inputs.
Industry experts view this as a strategic milestone for biopesticide producers and sustainable agriculture advocates, fostering long-term regulatory certainty for the development of eco-friendly formulations.
2026-09-09
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Global Countries Impose Tariffs on Chinese Chemical Products
-
Rare Earth and Power: Strategic Probing Beneath the New U.S.–China Trade Framework
-
U.S. Chemical Tariff Deadline Nears as the Industry Faces Cost Repricing and Supply-Chain Adjustment
-
EU Finalizes Anti-Dumping Duties on Chinese Adipic Acid as Chemical Trade Enters a Rule-Intensive Phase
-
EU Biocidal Data Protection Extension Raises the Stakes for Chemical Market Entry
-
China's National Narcotics Control Commission Issues Important Notice: Beware of These 8 Chemicals Being Diverted for Drug Production
-
API Supplier Audits Move to the Center of Pharma Supply Resilience
-
Supplement Recall Puts Nutrition Ingredient Safety Back Under Pressure
-
Chemours Sells Its Former Titanium Dioxide Site in Taiwan: Turning a “White Powder” Factory into “Wind Power Real Estate” for $360 Million—Buying Not Cash, But Breathing Room
-
The “Counter-Wind Ledger” of CHF 11.2 Billion: Sika Barely Grew in 2025—Yet Kept Taking Market Share
Recommend Reading
-
Smog Becomes a Sales Catalyst as Respiratory Drugs Surge in November
-
Vertex Pushes Gene Therapy Into Younger Children With Blood Disorders
-
Lilly’s Mounjaro Enters China’s State Insurance System
-
A New Obesity Pill Enters the Arena With Double-Digit Weight Loss
-
Japan’s Three Major Chemical Companies Join Forces to Weather Challenges in the Plastics Industry
-
Business Society’s PVC Market Outlook on September 4, 2026: Relatively Strong Fluctuations
-
Business Society’s Market Outlook for Dichloromethane on September 4, 2026: Volatile Fluctuations
-
Business Society’s Market Outlook for MIBK on September 4, 2026: Fluctuating Trend
-
Business Society’s Market Outlook for Phthalic Anhydride on September 4, 2026: Stagnant Growth
-
Business Society’s Market Outlook for Phthalic Anhydride on September 3, 2026: Volatile and Bearish